In clinical practice, theta burst stimulation (TBS) presents as a more efficient and potentially more effective therapeutic modality than conventional repetitive transcranial magnetic stimulation (rTMS), as it allows for the delivery of more stimuli in less time and at similar intensities. To date, accelerated treatment plans according to various continuous (cTBS) and intermittent TBS (iTBS) protocols for depression have been proposed. To investigate which of the TBS protocols provided a favorable risk-benefit balance for individuals with depression, this systematic review and random-effects model network meta-analysis was conducted. The study outcomes included response rate (primary), depression symptom improvement, remission rate, all-cause discontinuation rate, incidence of switch to mania, and incidence of headache/discomfort at treatment site. In this meta-analysis, a total of 23 randomized controlled trials (n = 960, mean age = 41.88 years, with 60.78% females) were included. Approximately 69.57% of the trials included individuals with an exclusive diagnosis of major depressive disorder. The following six TBS protocols (target) were evaluated: cTBS (right-dorsolateral prefrontal cortex [R-DLPFC]), cTBS (R-DLPFC) + iTBS (left-DLPFC [L-DLPFC]), iTBS (L-DLPFC), iTBS (L-DLPFC) + iTBS (R-DLPFC), iTBS (left-dorsomedial prefrontal cortex) + iTBS (right-dorsomedial prefrontal cortex), and iTBS (occipital lobe). Compared to sham, cTBS (R-DLPFC) + iTBS (L-DLPFC), iTBS (L-DLPFC), and iTBS (occipital lobe) had a higher response rate (k = 23); cTBS (R-DLPFC) + iTBS (L-DLPFC) and iTBS (L-DLPFC) dominated in the depression symptom improvement (k = 23); and iTBS (L-DLPFC) had a higher remission rate (k = 15). No significant differences were found for all-cause discontinuation rate (k = 17), incidence of switch to mania (k = 7), and incidence of headache/discomfort at treatment site (k = 10) between any TBS protocols and sham. Thus, cTBS (R-DLPFC) + iTBS (L-DLPFC) and iTBS (L-DLPFC) demonstrate favorable risk-benefit balance for the treatment of depression.

The efficacy and safety of deep transcranial magnetic stimulation (dTMS) in treating treatment-resistant depression (TRD) are unknown. Up to June 21, 2023, we conducted a systematic search for RCTs, and then extracted and synthesized data using random effects models. Five RCTs involving 507 patients with TRD (243 in the active dTMS group and 264 in the control group) were included in the present study. The active dTMS group showed significantly higher study-defined response rate (45.3% versus 24.2%, n = 507, risk ratio [RR] = 1.87, 95% confidence interval [CI]: 1.21-2.91, I² = 53%; P = 0.005) and study-defined remission rate (38.3% versus 14.4%, n = 507, RR = 2.37, 95%CI: 1.30-4.32, I² = 58%; P = 0.005) and superiority in improving depressive symptoms (n = 507, standardized mean difference = -0.65, 95%CI: -1.11--0.18, I² = 82%; P = 0.006) than the control group. In terms of cognitive functions, no significant differences were observed between the two groups. The two groups also showed similar rates of other adverse events and all-cause discontinuations (P > 0.05). dTMS is an effective and safe treatment strategy for the management of patients with TRD.

Transcranial magnetic stimulation (TMS) is a device-based neuromodulation technique increasingly used to treat brain diseases. Electric field (E-field) modeling is an important technique in several TMS clinical applications, including the precision stimulation of brain targets with accurate stimulation density for the treatment of mental disorders and the localization of brain function areas for neurosurgical planning. Classical methods for E-field modeling usually take a long computation time. Fast algorithms are usually developed with significantly lower spatial resolutions that reduce the prediction accuracy and limit their usage in real-time or near real-time TMS applications. This review paper discusses several modern algorithms for real-time or near real-time TMS E-field modeling and their advantages and limitations. The reviewed methods include techniques such as basis representation techniques and deep neural-network-based methods. This paper also provides a review of software tools that can integrate E-field modeling with navigated TMS, including a recent software for real-time navigated E-field mapping based on deep neural-network models.

Advances in brain stimulation have made it possible to target smaller and smaller regions for electromagnetic stimulation, in the hopes of producing increasingly focal neural effects. However, the brain is extensively interconnected, and the neurons comprising those connections may themselves be particularly susceptible to neurostimulation. Here, we test this hypothesis by identifying long-range projections in single-unit recordings from nonhuman primates receiving transcranial alternating current stimulation. We find that putative long-range projections are more strongly affected by stimulation than other cells. Specifically, they are both more entrained on average and account for occurrences of extremely strong entrainment. Given that stimulation appears to target the edges, rather than nodes, of neural networks, it may be necessary to rethink how neurostimulation strategies are designed.

Neuromodulation techniques have emerged as transformative tools for treating several neurological and psychiatric disorders, offering alternatives to traditional pharmacological approaches often hindered by the blood-brain barrier and off-target effects. While conventional modalities like deep brain stimulation, transcranial magnetic stimulation, and optogenetics have shown promise, they each face limitations in invasiveness, spatial resolution, or clinical applicability. In recent years, low-intensity ultrasound has gained attention as a noninvasive, deep-penetrating modality capable of modulating brain circuits with millimeter-sized spatial precision. This review explores the synergistic integration of ultrasound with engineered nanosystems to achieve multimodal neuromodulation such as electrical, mechanical, optical, and chemical via acoustic energy. We describe how nanoscale materials can transduce ultrasound into localized bioelectric signals, mechanical stress, light emission, or controlled drug release. These interactions enable precise, on-demand stimulation or inhibition of neuronal activity, including in deep brain regions. Experimental studies have demonstrated neuromodulatory effects across a variety of models, with applications ranging from optogenetics and drug delivery to behavioral modulation in rodents and primates. The review concludes with a critical assessment of the translational challenges such as nanoparticle delivery, biocompatibility, long-term clearance, and safety thresholds for human use while outlining promising strategies like cell-based delivery, biodegradable materials, and closed-loop control systems. These innovations highlight the potential of ultrasound-assisted nanosystems as transformative tools for precise neuromodulation in both experimental neuroscience and clinical applications.

non-invasive, widely approved therapy that uses magnetic fields to stimulate specific areas of the brain to treat depression, obsessive-compulsive disorder Electromagnetic therapy or electromagnetic field therapy is therapy involving the use of electromagnetic radiation to alter neuronal activity. This subfield of neurotherapy uses medical devices, such as magnets or electromagnets to treat mental and physical health disorders in patients. Types include : Bioelectromagnetics, the study of how electromagnetic fields interact with and influence biolog Bioelectromagnetics, the study of how electromagnetic fields interact with and influence biological processes. Electrotherapy, the use of electrical or electromagnetic energy in medicine; Electromagnetic therapy (alternative medicine), the use of electromagnetic radiation to treat disease. Evidence of efficacy is lacking. Pulsed electromagnetic field therapy, or PEMF, the use of weak electromagnetic fields to initiate osteogenesis. Alternating electric field therapy, also known as "Tumor Treating Fields", the use of electric fields as an anti-mitotic therapy for cancer patients. Transcranial magnetic stimulation (TMS), a non-invasive, widely approved therapy that uses magnetic fields to stimulate specific areas of the brain to treat depression, obsessive-compulsive disorder, and other neurological and psychiatric conditions, especially in patients who do not respond to medication, with strong clinical evidence supporting its effectiveness.

Major depressive disorder (MDD) is one of the most prevalent mental illnesses and, despite the availability of multiple treatment options, remains difficult to treat for a substantial proportion of patients. Repetitive transcranial magnetic stimulation (rTMS) is an important therapeutic approach for depression, modulating brain activity through targeted magnetic pulses in a non-invasive manner. This review examined scientific evidence from clinical trials, large-scale analyses, and laboratory investigations regarding the effectiveness and safety of rTMS, as well as its role within contemporary therapeutic strategies for depression. In addition to conventional rTMS, the review addresses theta-burst stimulation (TBS), deep TMS, and various approaches aimed at enhancing treatment efficacy or accelerating clinical response, while also discussing the practical utility of different stimulation devices. rTMS applied to specific regions of the prefrontal cortex has demonstrated significant antidepressant effects, and intermittent theta-burst stimulation (iTBS) appears to achieve comparable outcomes within a shorter time frame. Research further indicates that rTMS is associated with neurobiological changes in brain connectivity, modulation of neurotransmitter systems, and the promotion of neuroplasticity. Across studies, rTMS is generally considered safe, with reported adverse effects being mild and transient. However, further research is needed to optimize stimulation protocols, clarify medium and long-term effects, individualize treatment approaches, and determine the durability of therapeutic benefits.

targeted area of the brain through electromagnetic induction. A device called a stimulator generates electric pulses that are delivered to a magnetic Transcranial magnetic stimulation (TMS) is a noninvasive neurostimulation technique in which a changing magnetic field is used to induce an electric current in a targeted area of the brain through electromagnetic induction. A device called a stimulator generates electric pulses that are delivered to a magnetic coil placed against the scalp. The resulting magnetic field penetrates the skull and ind Tra… TMS uses electromagnetic induction to generate an electric current across the scalp and skull. A plastic-enclosed coil of wire is held next to the skull and when activated, produces a varying magnetic field oriented orthogonally to the plane of the coil. The changing magnetic field then induces an electric current in the brain that activates nearby nerve cells in a manner similar to a current applied superficially at the cortical surface. The magnetic field is about the same strength as magnetic resonance imaging (MRI), and the pulse generally reaches no more than 5 centimeters into the brain unless using a modified coil and technique for deeper stimulation. Transcranial magnetic stimulation is achieved by quickly discharging current from a large capacitor into a coil to produce pulsed magnetic fields between 2 and 3 teslas in strength. Directing the magnetic field pulse at a targeted area in the brain causes a localized electrical current which can then either depolarize or hyperpolarize neurons at that site. The induced electric field inside the brain tissue causes a change in transmembrane potentials resulting in depolarization or hyperpolarization of neurons, causing them to be more or less excitable, respectively. TMS…

A theoretical calculation of the electric field induced in the cortex during magnetic stimulation. We present a mathematical model for calculating the electric field induced in the head during magnetic stimulation of the cortex. The electric field arises from 2 sources: (1) the changing magnetic field creates an electric field in the tissue by electromagnetic induction, and (2) a charge distribution arises on the surface of the head and produces its own electrostatic field. A 3-sphere model is used to represent the brain, skull and scalp. The electric field as a function of the coil position, shape and orientation is computed numerically. The charge distribution partially shields the brain from the stimulus. The electric field is insensitive to the skull conductivity, in contrast with electrical stimulation using surface electrodes. Different coil shapes and orientations are considered, and a figure-of-eight coil is shown to deliver the largest and most focal stimulus. Published in Electroencephalography and clinical neurophysiology (1991)

Background the deployment of fifth-generation (5G) wireless telecommunications infrastructure, incorporating millimeter-wave (mmWave, 24-100 GHz) and sub-6 GHz frequencies, has renewed scientific and public health interest in the potential neurobiological effects of radiofrequency electromagnetic fields (RF-EMF). While extensive research has examined lower-frequency RF-EMF from 2G/3G/4G technologies, the specific effects of mmWave frequencies on CNS cellular biology-including microglial polarization and intracellular calcium signaling-remain less characterized. This systematic review evaluates experimental evidence from in vitro and in vivo studies on the effects of high-frequency EMF (300 MHz-300 GHz) on neuroimmune responses, microglial function, CNS calcium homeostasis, and related outcomes. Methods PubMed, EMBASE, Web of Science, and the EMF-Portal were searched from inception to January 2026 following PRISMA 2020 guidelines. Experimental (in vitro and animal) studies reporting CNS-relevant outcomes after high-frequency RF-EMF exposure were eligible. Exposure must have been within the 300 MHz to 300 GHz range. Quality assessment used adapted OHAT risk-of-bias criteria. A narrative synthesis was conducted; quantitative pooling was performed where three or more studies reported the same outcome. Results forty-one studies met inclusion criteria (see PRISMA Flow Diagram, Fig. 1): 7 in vitro (cell culture), 29 in vivo (rodent model), and 5 reviews/meta-analyses. The detailed characteristics of all included studies are summarized in Table 1. At specific absorption rate (SAR) levels at or below the International Commission on Non-Ionizing Radiation Protection (ICNIRP) general public exposure guidelines (2 W/kg averaged over 10 g), the majority of studies (27/41, 66%) found no statistically significant effects on neuroinflammatory markers, microglial morphology, or calcium signaling. Eleven studies (27%) reported transient, low-magnitude increases in intracellular Ca²⁺ or pro-inflammatory cytokine expression at exposures near or exceeding guideline limits; these effects were not consistently reproducible across independent laboratories. Three studies (7%) reported effects below guideline thresholds that may warrant further investigation. No study identified neuropathological changes (neuronal death, axonal injury) attributable to RF-EMF at guideline-compliant exposures. Conclusions current experimental evidence does not establish that high-frequency RF-EMF at guideline-compliant exposure levels produces significant adverse effects on microglial polarization, CNS calcium homeostasis, or neuroinflammatory responses. Methodological heterogeneity, inadequate dosimetry, and limited independent replication constrain confidence in both positive and negative findings. Standardized, rigorously controlled experimental studies are needed, particularly for mmWave frequencies (> 6 GHz) where data are sparse. Our findings support the current scientific consensus that high-frequency RF-EMF below regulatory limits does not pose a clearly established neurobiological hazard.

Magnetic Particle Imaging (MPI) is a promising modality which uses Magnetic Nanoparticles (MNPs) for tracer-based imaging in biomedical applications. Aside from their use in imaging, MNPs are increasingly being utilized for therapeutics, controlled targeted drug delivery, and diagnostics. These techniques depend on the behavior of MNPs when exposed to alternating magnetic field of a certain frequency and amplitude. However, the frequency typically used for imaging is 25kHz, while the transduction behaviors desired for these biomedical applications are seen at low radio-frequencies and higher amplitude fields than ones used for imaging. This work presents a high frequency electromagnetic coil which fulfills operational, safety, and geometric parameters necessary for incorporation in a custom MPI system and will allow us to simultaneously image and stimulate at specific locations within the body of a mouse. Optimization of the instrument is done through experimentation and electromagnetic theory, with focuses on parasitic elements and metallurgical phenomena. A resonant tank and direct cooling with a water pump allows for increased field strength while maintaining thermal and radio-frequency energy absorption standards for in vivo experiments.